NCT04673149View on ClinicalTrials.gov

GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

March 3, 2021

Study Completion Date

May 10, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

GLS-5310

GLS-5310 DNA plasmid vaccine

BIOLOGICAL

Placebo

Placebo

Trial Locations (1)

08308

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

GeneOne Life Science, Inc.

INDUSTRY

NCT04673149 - GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19) | Biotech Hunter | Biotech Hunter